Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
Soejima
Makoto
M
Kawaguchi
Yasushi
Y
Hara
Masako
M
Kamatani
Naoyuki
N
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012460:Sulfasalazine / Q000009:adverse effects*
D018501:Antirheumatic Agents; D012460:Sulfasalazine; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human